Center for Public Health Practice

Helena-West Helena, AR, United States

Center for Public Health Practice

Helena-West Helena, AR, United States
Time filter
Source Type

News Article | May 17, 2017

The University of Pittsburgh Graduate School of Public Health has selected Wendy Elizabeth Braund, M.D., M.P.H., M.S.Ed., F.A.C.P.M., as the new director of its Center for Public Health Practice and associate dean for public health practice. She will join the school’s faculty as a professor in the Department of Health Policy and Management. Braund, who has a strong history in public health administration, most recently served as state health officer and public health division administrator for the Wyoming Department of Health. She will join Pitt Public Health on July 1. “Dr. Braund is a leader in public health practice and preventive medicine on a national stage, and we are proud to have her guide our efforts to move public health research and policy into practical application,” said Donald S. Burke, M.D., Pitt Public Health dean and UPMC-Jonas Salk chair of global health. “She is a dynamic and innovative practitioner with extensive experience in public service and policy. I am confident she will craft and lead a strategic vision for the center’s future and continue to build on regional collaborations to improve population health.” Pitt Public Health’s Center for Public Health Practice was established in 1995 with a mission of linking academia with professional public health practice to contribute to better health for all Pennsylvanians. The center has a strong focus on education and runs or provides support for programs that train public health practitioners in the latest best practices for their professional fields. It also places dozens of master’s and doctoral students in internships with public health agencies annually. “The Center for Public Health Practice at Pitt Public Health is an invaluable resource for state and local health regulators, public health organizations, emergency responders and other public health practitioners,” said Braund. “I’m excited to lead the center in new and innovative ways to bring research and practice together for the betterment of public health, while continuing the fantastic work its faculty, staff and partners perform every day.” Prior to the Wyoming Department of Health, Braund was with the U.S. Health Resources & Services Administration and served as chief of the Public Health Branch and acting chief of the Geriatrics and Allied Health Branch. Braund earned her M.D. from the Pennsylvania State University College of Medicine and completed a residency in preventive medicine at Johns Hopkins University. She earned her M.P.H. at the Johns Hopkins Bloomberg School of Public Health, and also earned degrees from the University of Pennsylvania and Duke University. She completed the executive education program for state health leaders at the Harvard Kennedy School of Government. She serves on the Board of Regents of the American College of Preventive Medicine, as a trustee of the American Board of Preventive Medicine, and as a representative to the American Medical Association Section Council on Preventive Medicine, among other appointments. Since 2013 she has been a site reviewer on the Council on Education for Public Health. Gerald Barron, M.P.H., has served as acting director of the Pitt Public Health Center for Public Health Practice for the past two years. He will continue as deputy director of the center, director of the M.P.H. program in Pitt Public Health’s Department of Health Policy and Management, and associate professor of health policy and management, and behavioral and community health sciences. “Under Gerry’s stewardship, the center built and maintained strong relationships with state governments in our region, developed its faculty and enhanced its training programs,” said Burke. “We all thank him for his service.”

Powell S.E.,Centers for Disease Control and Prevention | Hariri S.,Centers for Disease Control and Prevention | Steinau M.,Centers for Disease Control and Prevention | Bennett N.M.,University of Rochester | And 5 more authors.
Vaccine | Year: 2012

Background: Vaccination against human papillomavirus (HPV) types 16 and 18 is recommended for girls aged 11 or 12 years with catch-up vaccination through age 26 in the U.S. Cervical intraepithelial neoplasia (CIN) grade 2 or 3 and adenocarcinoma in situ (CIN2+) are used to monitor HPV vaccine impact on cervical disease. This report describes vaccination status in women diagnosed with CIN2+ and examines HPV vaccine impact on HPV 16/18-related CIN2+. Methods: As part of a vaccine impact monitoring project (HPV-IMPACT), females 18-31 years with CIN2+ were reported from pathology laboratories in CA, CT, NY, OR, TN from 2008 to 2011. One diagnostic block was selected for HPV DNA typing with Roche Linear Array. Demographic, abnormal Papanicolaou (Pap) test dates and vaccine status information were collected. The abnormal Pap test immediately preceding the CIN2+ diagnosis was defined as the 'trigger Pap'. Results: Among 5083 CIN2+ cases reported to date, 3855 had vaccination history investigated; 1900 had vaccine history documented (vaccinated, with trigger Pap dates, or unvaccinated). Among women who initiated vaccination >24 months before their trigger Pap, there was a significantly lower proportion of CIN2+ lesions due to 16/18 compared to women who were not vaccinated (aPR.=.67, 95% CI: .48-.94). Among the 1900 with known vaccination status, 20% initiated vaccination on/after their trigger screening. Women aged 21-23 years were more likely to initiate vaccination on/after the trigger Pap compared to 24-26 year olds (29.0% vs. 19.6%, p=001), as were non-Hispanic blacks compared to non-Hispanic whites (27.3% vs. 19.0%, p=001) and publicly compared to privately insured women (38.1% vs. 17.4%, p< 0001). Conclusion: We found a significant reduction in HPV 16/18-related lesions in women with CIN2+ who initiated vaccination at least 24 months prior to their trigger Pap. These preliminary results suggest early impact of the HPV vaccine on vaccine-type disease, but further evaluation is warranted. © 2012 .

Hariri S.,Centers for Disease Control and Prevention | Unger E.R.,Centers for Disease Control and Prevention | Schafer S.,Center for Public Health Practice | Bloch K.C.,Vanderbilt University | And 4 more authors.
Cancer Epidemiology Biomarkers and Prevention | Year: 2015

Background: Two currently available vaccines targeting human papillomavirus (HPV) types 16 and 18 could prevent 70% of cervical cancers and 50% of high-grade cervical lesions. Next-generation vaccines against additional types, such as a candidate 9-valent vaccine against HPV6/11/16/18/31/33/45/52/58, could further reduce HPV-associated disease burden.Methods: HPV was typed in archived tissues from women ages 21 to 39 years residing in five catchment areas in the United States with cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+) using L1 consensus PCR and type-specific hybridization. Type attribution was estimated using weights to account for lesions with multiple types detected.Results: From 2008 to 2011, 5,498 of 6,306 (87.2%) specimens obtained from 8,469 women with CIN2+ had valid typing results; HPV DNA was detected in 97.3%. Overall, 50.1% of lesions were attributable to HPV16/18, ranging from 50.3% to 52.4% among those ages 21 to 34 years, and significantly declined in 35 to 39 year-olds (43.5%). HPV16/18 attribution was higher in non-Hispanic whites (56.4%) versus racial/ethnic minorities (range, 41.8%-45.9%; P < 0.001). HPV31/33/45/52/58 attribution was 25.0% overall and increased with age (P < 0.001). A higher proportion of CIN2+ was attributable to HPV31/33/45/52/58 in non-Hispanic black (29.9%), Hispanic (29.2%), and Asian (33.1%) women compared with non-Hispanic whites (22.8%; P < 0.001).Conclusions: Overall, 75% of lesions were attributable to 7 oncogenic HPV types: 50% to HPV16/18 and 25% to HPV31/33/45/52/58. HPV16/18 had the largest attributable fraction in CIN2+ across all subpopulations, although to a lesser extent in older women and racial/ethnic minorities.Impact: Vaccines targeting additional oncogenic HPV types could prevent more high-grade cervical lesions, especially among racial/ethnic minorities. © 2014 American Association for Cancer Research.

Hariri S.,Centers for Disease Control and Prevention | Bennett N.M.,University of Rochester | Niccolai L.M.,P.A. College | Schafer S.,Center for Public Health Practice | And 9 more authors.
Vaccine | Year: 2015

Background: Prevention of pre-invasive cervical lesions is an important benefit of HPV vaccines, but demonstrating impact on these lesions is impeded by changes in cervical cancer screening. Monitoring vaccine-types associated with lesions can help distinguish vaccine impact from screening effects. We examined trends in prevalence of HPV 16/18 types detected in cervical intraepithelial neoplasia 2, 3, and adenocarcinoma in situ (CIN2+) among women diagnosed with CIN2+ from 2008 to 2012 by vaccination status. We estimated vaccine effectiveness against HPV 16/18-attributable CIN2+ among women who received ≥1 dose by increasing time intervals between date of first vaccination and the screening test that led to detection of CIN2+ lesion. Methods: Data are from a population-based sentinel surveillance system to monitor HPV vaccine impact on type-specific CIN2+ among adult female residents of five catchment areas in California, Connecticut, New York, Oregon, and Tennessee. Vaccination and cervical cancer screening information was retrieved. Archived diagnostic specimens were obtained from reporting laboratories for HPV DNA typing. Results: From 2008 to 2012, prevalence of HPV 16/18 in CIN2+ lesions statistically significantly decreased from 53.6% to 28.4% among women who received at least one dose (Ptrend<.001) but not among unvaccinated women (57.1% vs 52.5%; Ptrend=08) or women with unknown vaccination status (55.0% vs 50.5%; Ptrend=71). Estimated vaccine effectiveness for prevention of HPV 16/18-attributable CIN2+ was 21% (95% CI: 1-37), 49% (95% CI: 28-64), and 72% (95% CI: 45-86) in women who initiated vaccination 25-36 months, 37-48 months, and >48 months prior to the screening test that led to CIN2+ diagnosis. Conclusions: Population-based data from the United States indicate significant reductions in CIN2+ lesions attributable to types targeted by the vaccines and increasing HPV vaccine effectiveness with increasing interval between first vaccination and earliest detection of cervical disease. © 2015.

Hariri S.,Centers for Disease Control and Prevention | Johnson M.L.,Centers for Disease Control and Prevention | Bennett N.M.,University of Rochester | Bauer H.M.,Center for Public Health Practice | And 4 more authors.
Cancer | Year: 2015

BACKGROUND Cervical intraepithelial neoplasia grade 2, 3, and adenocarcinoma in situ (CIN2+) lesions can be monitored as early indicators of human papillomavirus (HPV) vaccine impact. Changes to screening utilization will affect observed reductions in CIN2+ rates and complicate the interpretation of vaccine impact. METHODS From 2008 to 2012, 9119 cases of CIN2+ among 18- to 39-year-old residents of catchment areas in California, Connecticut, New York, and Oregon were reported to the HPV-IMPACT Project, a sentinel system for monitoring the population impact of HPV vaccine. Age-stratified CIN2+ incidence rates were calculated for each catchment. Annual cervical screening was estimated for California, New York, and Oregon catchments with administrative and survey data. The Cochran-Armitage test was used to examine trends. RESULTS From 2008 to 2012, the incidence of CIN2+ significantly decreased among 18- to 20-year-olds (California, from 94 to 5 per 100,000 women; Connecticut, from 450 to 57 per 100,000 women; New York, from 299 to 43 per 100,000 women; and Oregon, from 202 to 37 per 100,000 women; Ptrend<.0001) and among 21- to 29-year-olds in Connecticut (from 762 to 589 per 100,000 women) and New York (from 770 to 465 per 100,000 women; Ptrend<.001); rates did not differ among 30- to 39-year-olds. During the same period, screening rates also declined, with the largest decreases among 18- to 20-year-olds (from 67% in Oregon to 88% in California) and with smaller declines among 21- to 29-year-olds (13%-27%) and 30- to 39-year-olds (3%-21%). CONCLUSIONS The declines in CIN2+ detection in young women were likely due to reduced screening but could also reflect the impact of vaccination. These data illustrate challenges in interpreting CIN2+ ecologic trends in the new era of cervical cancer prevention and emphasize the importance of information such as HPV types detected in lesions to assess the impact of HPV vaccine on cervical precancers. Cancer 2015;121:2775-2781. © 2015 American Cancer Society Significant declines in high-grade cervical lesions in young women since 2008 are likely due to reduced cervical cancer screening but could also reflect vaccine impact. © 2015 American Cancer Society.

Smith N.,Center for Public Health Practice | Keiser P.,University of Texas Medical Branch | Naicker S.,University of Witwatersrand | Tonelli M.,Public Health science | Tonelli M.,University of Alberta
Clinical Infectious Diseases | Year: 2010

Background. The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals. Methods. MEDLINE, EMBASE, Global Health, Scopus, Biosis Previews, Cochrane Library, Web of Science, and existing systematic reviews were searched. Prospective studies comparing TDF-containing with non-TDF containing ART regimens were selected for inclusion. We extracted data on study characteristics, participant characteristics, therapeutic interventions, renal function, bone density, and fracture rates. Results. A total of 17 studies (including 9 randomized, controlled trials) met the selection criteria. Median sample size was 517 participants. Constituent ART regimens were diverse. There was a significantly greater loss of kidney function among the TDF recipients, compared with control subjects (mean difference in calculated creatinine clearance, 3.92 mL/min; 95% confidence interval [CI], 2.13-5.70 mL/min), as well as a greater risk of acute renal failure (risk difference, 0.7%; 95% CI, 0.2-1.2). There was no evidence that TDF use led to increased risk of severe proteinuria, hypophosphatemia, or fractures. Conclusions. Although TDF use was associated with a statistically significant loss of renal function, the clinical magnitude of this effect was modest. Our findings do not support the need to restrict TDF use in jurisdictions where regular monitoring of renal function and serum phosphate levels is impractical. © 2010 by the Infectious Diseases Society of America.

Zilversmit L.,Centers for Disease Control and Prevention | Sappenfield O.,Centers for Disease Control and Prevention | Zotti M.,Centers for Disease Control and Prevention | McGehee M.A.,Center for Public Health Practice
Women's Health Issues | Year: 2014

Purpose: Having an emergency plan may reduce negative effects of disaster on the health of postpartum women and their infants. However, little is known about the prevalence of emergency plans among postpartum women. In 2009, Arkansas added a question to the Pregnancy Risk Assessment Monitoring System surveillance system about whether women who gave birth that year had an emergency plan. In this study, we first describe the sociodemographic characteristics, disaster experience, and region of residence of postpartum women in Arkansas who indicated that they had an emergency plan for their families in 2009, and second, examine associations between sociodemographic characteristics and disaster experience and the presence of an emergency plan. Methods: Multivariable logistic regression (n=1,173) was conducted to examine associations between maternal race/ethnicity, sociodemographic characteristics, region of residence, disaster experience, and having a disaster plan. We adjusted for maternal education, federal poverty level, and family size in our final model. Findings: Forty-eight percent (n=559) of women reported having an emergency plan. Hispanic women were less likely to report having a plan compared with non-Hispanic White women (n=102 [10%]; adjusted prevalence ratio [aPR], 0.6; 95% confidence interval [CI], 0.4-0.9). Families with five or more members were more likely to have a plan compared with smaller families (n=123 [11%]; aPR, 1.3; 95% CI, 1.1-1.6). Conclusions: Policymakers and public health practitioners can use these results to promote emergency planning among postpartum women in Arkansas, with special outreach to postpartum women who are Hispanic or have smaller families. © 2014 Jacobs Institute of Women's Health.

Martinez M.E.,University of California at San Diego | Jacobs E.T.,University of Arizona | Baron J.A.,Arizona Cancer Center | Marshall J.R.,University of North Carolina at Chapel Hill | And 2 more authors.
Journal of the National Cancer Institute | Year: 2012

Nutritional supplementation is now a multibillion-dollar industry, and about half of all US adults take supplements. Supplement use is fueled in part by the belief that nutritional supplements can ward off chronic disease, including cancer, although several expert committees and organizations have concluded that there is little to no scientific evidence that supplements reduce cancer risk. To the contrary, there is now evidence that high doses of some supplements increase cancer risk. Despite this evidence, marketing claims by the supplement industry continue to imply anticancer benefits. Insufficient government regulation of the marketing of dietary supplement products may continue to result in unsound advice to consumers. Both the scientific community and government regulators need to provide clear guidance to the public about the use of dietary supplements to lower cancer risk. © The Author(s) 2012.

Bondurant K.L.,University of Arkansas for Medical Sciences | Harvey S.,Center for Public Health Practice | Klimberg S.,University of Arkansas for Medical Sciences | Kadlubar S.,University of Arkansas for Medical Sciences | Phillips M.M.,University of Arkansas for Medical Sciences
Breast Journal | Year: 2011

Breast cancer continues to be among the most common cancers affecting women in the United States. Researchers investigating the area are turning their attention to novel prevention, detection, and treatment options. Recent molecular epidemiology research has highlighted the effects of both genetic and environmental exposures on an individual's risk of developing breast cancer and predicted response to treatment. Cohort designs are a potentially powerful tool that researchers can utilize to investigate the genetic and environmental factors affecting breast cancer risk and treatment options. This paper describes the recruitment of a community-based cohort of women in a southern state. The Spit for the Cure Cohort (SFCC), being developed by researchers at the University of Arkansas for Medical Sciences (Little Rock, AR), is designed to be representative of the female population of the state with oversampling of women with a history of breast cancer and women of color. To date, the SFCC includes more than 14,000 women recruited from all 75 counties of Arkansas and six neighboring states. Methods used to recruit and maintain the cohort and collect both questionnaire data and genetic material are described, as are the demographic characteristics of the cohort as it currently exists. The recruitment methods utilized for the SFCC are rapidly building a breast cancer cohort and providing a large biorepository for molecular epidemiology research. © 2011 Wiley Periodicals, Inc.

PubMed | Centers for Disease Control and Prevention, Center for Public Health Practice and 3 Adolescent Health Promotion and STD HIV HCV Programs
Type: Journal Article | Journal: AIDS patient care and STDs | Year: 2016

Substantial increases in syphilis during 2008-2013 were reported in the US Pacific Northwest state of Oregon, especially among men who have sex with men (MSM). The authors aimed to characterize the ongoing epidemic and identify possible gaps in clinical management of early syphilis (primary, secondary, and latent syphilis 1 year) among MSM in Multnomah County, Oregon to inform public health efforts. Administrative databases were used to examine trends in case characteristics during 2008-2013. Medical records were abstracted for cases occurring in 2013 to assess diagnosis, treatment, and screening practices. Early syphilis among MSM increased from 21 cases in 2008 to 229 in 2013. The majority of cases occurred in HIV-infected patients (range: 55.6%-69.2%) diagnosed with secondary syphilis (range: 36.2%-52.4%). In 2013, 119 (51.9%) cases were diagnosed in public sector medical settings and 110 (48.0%) in private sector settings. Over 80% of HIV-infected patients with syphilis were in HIV care. Although treatment was adequate and timely among all providers, management differed by provider type. Among HIV-infected patients, a larger proportion diagnosed by public HIV providers than private providers were tested for syphilis at least once in the previous 12 months (89.6% vs. 40.0%; p<0.001). The characteristics of MSM diagnosed with early syphilis in Multnomah County remained largely unchanged during 2008-2013. Syphilis control measures were well established, but early syphilis among MSM continued to increase. The results suggest a need to improve syphilis screening among private clinics, but few gaps in clinical management were identified.

Loading Center for Public Health Practice collaborators
Loading Center for Public Health Practice collaborators